Medical/Pharmaceuticals
Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics
SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a lar...
2026-03-25 21:01
6178
Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics
- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the...
2026-03-25 20:00
4570
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company
BEIJING, March 25, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics ...
2026-03-25 20:00
5360
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. Th...
2026-03-25 18:22
6031
HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering
Listing milestone positions HanchorBio to strengthen institutional visibility, advance itsFBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases TAIPEI, SHANGHAI and SAN FRANCISCO, March 25, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a globa...
2026-03-25 18:00
4914
VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial
* Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 * A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment * Fully biological transplant eliminates need for immunosuppres...
2026-03-25 17:11
3934
BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States
BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing SUZHOU, China, March 25, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (SSE: 688166, "BrightGene" or "the Company") today announced positive topline results f...
2026-03-25 14:32
4312
Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first...
2026-03-25 10:40
5975
From SCAN to SPARK: Galaxy Brain Scientific Enables a New Paradigm in Non-invasive, Personalized Precision Treatment for Parkinson's Disease
BEIJING, March 24, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study in Nature Neuroscience demonstrating that Deep Brain Stimulation (DBS) achieves therapeutic efficacy in Parkinson's disease...
2026-03-25 10:34
4242
Hope Medicine Announces First Patient Dosed in the Phase III Clinical Trial for Endometriosis
SHANGHAI, March 24, 2026 /PRNewswire/ -- Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III clinical trial of HMI-115, its first-in-class monoclonal antibody with global rights, for the treatm...
2026-03-25 08:08
5376
Fosun Pharma Announces 2025 Annual Results
Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual operating r...
2026-03-24 22:47
5270
Datasea (NASDAQ: DTSS) Announces Initial U.S. Commercial Rollout and Commercialization Pathway for Acoustic Technology-Enabled Wellness Care Robots
Early-stage deployments across multiple U.S. regions expected to support initial service revenue generation and scalable commercialization model BEIJING, March 24, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in acoustic high-te...
2026-03-24 21:30
5630
HKeyBio Launches HKEY-NHP-onChip™ 1.1: World's First NHP In Vitro Model for Autoimmune and Allergic Diseases
The integrated organ-on-chip platform offers 10–100x cost efficiency and 80% reduction in animal use, bridging the gap between preclinical NHP research and human clinical success. SUZHOU, China, SAN FRANCISCO and BOSTON, March 24, 2026 /PRNewswire/ -- HKeyBio, a global leading CRO specializing in...
2026-03-24 20:30
3814
WuXi Biologics Reports Record 2025 Annual Results
* Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY * IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) * EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY; ...
2026-03-24 19:44
5165
Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized p...
2026-03-24 18:29
4036
GCCL Showcases RSV FRNT Research and Integrated Bioanalytical Capabilities at World Vaccine Congress 2026
YONGIN, South Korea, March 24, 2026 /PRNewswire/ -- GCCL Co., Ltd. (GCCL), a global clinical trial laboratory services provider, announced that it will attend World Vaccine Congress 2026 (WVC 2026), taking place from March 30 to April 2 in Washington, D.C., where it will operate an exhibition boo...
2026-03-24 17:35
3584
The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China
* 73% of participants achieved Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W. SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharma...
2026-03-24 08:00
5098
WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
* Revenue increased by 46.7% YoY to RMB 5,944 million * Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024 * Adjusted net profit increased by 69.9% YoY to RMB 1,559 million, with its margin of 26.2%, a 3.6 percen...
2026-03-23 21:15
6119
Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine
("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven
drug discovery company, today announced the launch ofPandaClaw, a
transformative new feature of thePandaOmics
2026-03-23 20:30
5316
Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 22, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today announ...
2026-03-23 11:14
5507
Week's Top Stories
Most Reposted
Vietnam Explores Sustainable Aviation Fuel Development at International Conference in Hanoi
[Picked up by 301 media titles]
2026-06-25 14:33
MetaOptics Begins Shipment of Metalens Smartphone and AI Smart Glasses to European and Japanese Customers for Evaluation
[Picked up by 300 media titles]
2026-06-26 18:11IPD and ABB Help Power Sustainable Operations at New Sydney Fish Market
[Picked up by 298 media titles]
2026-06-22 17:40
SPHERE AX Partners with U.S. AI Semiconductor Company Blaize at the National Assembly
[Picked up by 293 media titles]
2026-06-24 18:00
BELLUSTAR TOKYO Ranked No. 10 Among Japan's Best City Hotels in Prestigious Award Chosen by Asia-Pacific Travelers
[Picked up by 290 media titles]
2026-06-24 12:00
Most Read
Korean Skincare Brand Meditherapy Tops Amazon U.S. Facial Serums, Breaking Into Beauty Best Sellers Top 20
2026-06-26 21:00
3421
National Book Store Partners with Anchanto to accelerate success across Online Channels & 260+ Retail Locations
2026-06-23 08:00
3164
Quantifind Announces $200 Million Growth Investment Led by Summit Partners to Advance AI-native Risk Intelligence and Governed Agentic Middleware for Modern Risk Operations
2026-06-26 21:00
3025
